Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, And Dexamethasone In Patients With Newly Diagnosed Multiple Myeloma

This phase 1 study aimed to determine the maximum tolerated dose, activity, and tolerability of vorinostat plus bortezomib, lenalidomide, and dexamethasone (R2V2) as induction therapy for newly diagnosed multiple myeloma. R2V2 resulted in remarkable response rates at the cost of increased toxicity. Future studies will identify the best partner for the standard R2V2 combination.Introduction: Bortezomib plus lenalidomide and dexamethasone (VRD) is a standard induction therapy for newly diagnosed multiple myeloma (NDMM) patients. Given preclinical and clinical data suggesting the synergistic activity of the histone deacetylase inhibitor vorinostat with both bortezomib and lenalidomide for the treatment of multiple myeloma, we hypothesized that adding vorinostat to VRD (R2V2) would increase the rate and the quality of responses to induction treatment. Here we report the results of a phase 1 trial (NCT01038388) evaluating R2V2 as up-front treatment for NDMM patients. Patients and Methods: R2V2 was tested as induction therapy in a dose-escalation phase 1 study in 30 NDMM patients deemed eligible for autologous stem-cell transplantation. Treatment consisted of 4 induction cycles with R2V2, followed by either autologous stem-cell transplantation or 4 additional R2V2 cycles and lenalidomide maintenance therapy. Results: The maximum tolerated dose of vorinostat was 200 mg daily. The most common adverse events were gastrointestinal (87%), fatigue and peripheral neuropathy (60%), and thrombocytopenia (33%). R2V2 induced an objective response in 96% of patients, with 48% obtaining at least a complete remission. Median progression-free survival was 52 months, with 77% of patients alive at 5 years. Conclusion: R2V2 as induction treatment for NDMM patients resulted in remarkable response rates at the cost of increased toxicity. (C) 2020 Elsevier Inc. All rights reserved.